LAS VEGAS - s4story -- Cardiff Lexington Corporation (Stock Symbol: CDIX), a targeted healthcare holding company specializing in orthopedic, spine, and pain-management clinic acquisitions, continues its aggressive growth trajectory in 2025. The company is demonstrating both operational execution and financial momentum, underscored by triple-digit quarterly growth, expanding clinical capabilities, and significant strategic progress toward uplisting.

Record Financial Growth in 2025

CDIX reported exceptional third-quarter 2025 results, showing dramatic expansion across all major financial metrics:

• Q3 2025 Revenue: Up 125.6% to $3.1 million
• Q3 2025 Gross Profit: Up 437.8% to $1.9 million
• Q3 2025 Income from Continuing Operations: Up 209.9% to $643,000

Year-to-date performance further demonstrates consistent execution:

• YTD Revenue: Up 70.2% to $8.8 million, compared to $5.1 million in the first nine months of 2024
• YTD Gross Profit: Up 126.2% to $5.4 million
• YTD Operating Income: Increased to $1.8 million, compared with a 2024 loss
• Total Assets: Increased 15.4% to $27.6 million

These results reinforce the strength of the company's scalable healthcare platform and its focused acquisition strategy.

A Healthcare Platform Built for Growth

All current CDIX revenues are generated through its subsidiary Nova Ortho and Spine, LLC, which operates a growing network of orthopedic, spine, and pain-management centers across Florida and Georgia. These centers deliver:

• Comprehensive diagnostic and surgical services
• Interventional pain management
• Primary care evaluations
• Specialty orthopedic and spinal consultations

CDIX's model targets middle-market niche clinics that provide high-demand medical services—an area of the healthcare sector known for strong margins and consolidation opportunities.

More on S For Story

• Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
• AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
• IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
• Are You Hiring The Right Heater Repair Company in Philly?
• Appliance EMT Expands Professional Appliance Repair Services to Hartford, Connecticut

First Procedures Completed at Doctor's Memorial Hospital: Expanding Access to Rural Florida

On December 11th, CDIX announced a major operational milestone: Nova Ortho and Spine successfully performed its first procedures at Doctor's Memorial Hospital in Perry, Florida.

This expansion represents more than growth—it signals a direct commitment to bringing high-quality orthopedic and pain-management care to severely underserved rural patient populations.

CEO Alex Cunningham commented:

"Our presence at Doctor's Memorial Hospital reinforces our commitment to providing best-in-class, accessible healthcare to the underserved and more rural areas around Florida. We quickly mobilized to bring our leading pain management and orthopedic and spinal surgical procedures to Taylor County, and we look forward to expanding into additional regions where we can further enhance healthcare standards and practices."

This hospital integration is expected to support continued revenue growth while positioning CDIX as a regional leader in bridging healthcare gaps across the Southeast.

Strengthening Corporate Governance and Uplisting Readiness

A key part of CDIX's growth strategy is its planned uplist to a senior exchange. Advancing that effort, the company recently entered into an advisory agreement with Greentree Financial Group, Inc., a firm specializing in corporate governance, financial reporting, and public-market compliance.

Greentree will guide CDIX on:

• Audit processes
• S-1 filing preparation
• SEC and exchange responses
• Governance enhancements
• Coordination with attorneys, CPAs, and transfer agents

This engagement underscores the company's commitment to financial discipline, transparency, and readiness to scale as a next-generation healthcare platform.

More on S For Story

• Java Holdings LLC Acquires +Peptide, Expanding Portfolio Across Coffee, Science, and Functional Nutrition
• First Audiobook Wins Outstanding Creator Awards For Historical Fiction & Other Categories
• Author Michelle Carey Releases Free Fiction and Non-Fiction eBooks to Spark Creative Growth
• OneSolution® Expands to Orlando with New Altamonte Springs Implant Center
• Beyond the Book: Clarity & Purpose with Award-Winning Author Renee Daniel Flagler

A Compelling Growth Story for Healthcare Investors

Cardiff Lexington has positioned itself at the intersection of rapidly growing healthcare demand, operational scalability, and underserved-market expansion. With a proven clinic-acquisition model and a successful track record of integrating and growing specialty medical centers, CDIX is strengthening its foundation for long-term value creation.

Investors watching the small-cap healthcare space may find CDIX's trajectory notable:

• Strong balance-sheet expansion
• Triple-digit improvements in profitability
• Strategic partnerships supporting an uplisting path
• Continued expansion into high-need medical markets

As CDIX accelerates its footprint and advances its strategy, the company appears well-positioned for continued growth in 2026 and beyond.

For More Information

Cardiff Lexington Corporation (Stock Symbol: CDIX)
CEO: Alex Cunningham
Email: investorsrelations@cardifflexington.com
Phone: (800) 628-2100 ext. 705
Website: https://cardifflexington.com/

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website